Skip to main content
. 2019 Oct 1;8(10):1566. doi: 10.3390/jcm8101566

Figure 3.

Figure 3

Kaplan–Meier curve for RECIST-PFS (A) and OS (B) based on the expression of PD-L2 defined as ≥1% vs. <1% in the Nivolumab Cohort. No significant difference was observed on the basis of PD-L2 expression.